hepatitis C hepatitis C

The newly approved Harvoni tablets bring several advances to the fight against hepatitis C, but they also have a steep price tag, reported at $1,125 for a single dose. Gilead Sciences hide caption

toggle caption
Gilead Sciences

Walter Bianco's liver is severely damaged by hepatitis C, but insurers had refused to pay for the medications that could cure him. Alexandra Olgin for NPR hide caption

toggle caption
Alexandra Olgin for NPR

Walter Bianco's liver is severely damaged by hepatitis C, but insurers had refused to pay for the medications that could cure him. Alexandra Olgin for NPR hide caption

toggle caption
Alexandra Olgin for NPR

Medicare Backs Down On Denying Treatment For Hepatitis Patient

  • Download
  • <iframe src="https://www.npr.org/player/embed/312828866/312978146" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Advocates demonstrate in favor of cheaper generic drugs to treat hepatitis C in New Delhi on March 21. The disease is common among people who are HIV positive. Saurabh Das/AP hide caption

toggle caption
Saurabh Das/AP

A girl with hepatitis C holds a medical report while being treated at a hospital in Hefei, China, in 2011. China has one of the greatest burdens of hepatitis C, but it's still not clear whether a deal for lower prices for a new drug from Gilead Sciences will apply there. Barcroft Media/Landov hide caption

toggle caption
Barcroft Media/Landov

Timothy Webb and other advocates protest the cost of HIV drugs manufactured by the pharmaceutical company Gilead outside an AIDS conference in Atlanta in March. Gilead is making a new hepatitis C drug, Sovaldi. John Amis/AP Images for AIDS Healthcare Foundation hide caption

toggle caption
John Amis/AP Images for AIDS Healthcare Foundation

$1,000 Pill For Hepatitis C Spurs Debate Over Drug Prices

  • Download
  • <iframe src="https://www.npr.org/player/embed/256885858/258301793" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

A colorized closeup of the hepatitis C virus. James Cavallini/Science Source hide caption

toggle caption
James Cavallini/Science Source

FDA Expected To Approve New, Gentler Cure For Hepatitis C

  • Download
  • <iframe src="https://www.npr.org/player/embed/248934833/248935208" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Particles of the hepatitis C virus are imaged with an electron microscope. James Cavallini/Science Source hide caption

toggle caption
James Cavallini/Science Source

Hepatitis C patient Nancy Turner shows Kathleen Coleman, a nurse practitioner, where a forearm rash, a side effect of her treatment, has healed. Turner is one of many patients with hepatitis C experimenting with new drugs to beat back the virus. Richard Knox/NPR hide caption

toggle caption
Richard Knox/NPR

As Hepatitis C Sneaks Up On Baby Boomers, Treatment Options Grow

  • Download
  • <iframe src="https://www.npr.org/player/embed/167258972/169305315" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Hospitals began testing blood for hepatitis in 1992, so anyone who received a blood transfusion before then is at an increased risk for contracting the disease. iStockphoto hide caption

toggle caption
iStockphoto